ProKidney Corp. - Class A Ordinary Shares PROK 深 沪
等待开盘 08-20 09:30:00 美东时间
2.34
-0.200
-7.87%
华盛通- 最 高2.52
- 今 开2.48
- 成交量 127.95万股
- 最 低 2.33
- 昨 收 2.54
- 总市值 3.11亿
- 52周最高 7.13
- 市盈率 静 --
- 换手率 0.96%
- 52周最低 0.4603
- 委 比 -40.13%
- 总股本 1.33亿
- 历史最高 14.19
- 量 比 0.56
- 振 幅 7.48%
- 历史最低 0.4603
- 每 手 1
- 风险率 0.80%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Chamath Palihapitiya Returns To SPACs: Past 18 Deals, Investments Average Loss Of 14%
Chamath Palihapitiya is back with a new SPAC. Many investors will remember past SPACs the investor was involved with and the poor performance track record.
08-19 23:53
Watching ProKidney Corp; Zacks Upgrades Stock To Strong Buy
https://www.zacks.com/stock/news/2589077/prokidney-cp-prok-upgraded-to-strong-buy-what-does-it-mean-for-the-stock
07-17 23:52
UBS Maintains Buy on ProKidney, Raises Price Target to $8
UBS analyst Eliana Merle maintains ProKidney (NASDAQ:PROK) with a Buy and raises the price target from $4 to $8.
07-15 22:23
Simulations Plus, FB Financial And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Nasdaq futures gaining ar...
07-15 20:40
ProKidney Confirms Alignment With FDA On Accelerated Approval Pathway For Rilparencel
FDA confirmed that eGFR slope is an acceptable surrogate endpoint for accelerated approval of rilparencel in patients with CKD and type 2 diabetesFDA also confirmed that the ongoing Phase 3 PROACT 1 study can be used for
07-15 19:31
ProKidney Announces Alignment with the FDA on the Accelerated Approval Pathway for Rilparencel
ProKidney Corp. announced alignment with the FDA on the accelerated approval pathway for rilparencel, an autologous cellular therapy for chronic kidney disease (CKD) with type 2 diabetes. The FDA confirmed that the slope of estimated glomerular filtration rate (eGFR) from the Phase 3 PROACT 1 study can serve as a surrogate endpoint for accelerated approval, with nearly half of required patients enrolled. Topline data for the accelerated approval ...
07-15 11:30
ProKidney Enters New $200M Sale Agreement with Jefferies
ProKidney ( ($PROK) ) has issued an update. On July 14, 2025, ProKidney Corp. e...
07-15 05:27
美股大行评级 | 潜在涨幅107.37%！花旗上调ProKidney目标价至9美元，维持"买入"评级
今日重点评级关注：花旗：维持ProKidney Corp. - Class A Ordinary Shares"买入"评级，目标价从6美元升至9美元；Canaccord Genuity：维持e.l.f. Beauty"买入"评级，目标价从114美元升至150美元
07-10 09:55
盘前：股指期货变动不大 交易员仍在努力摆脱关税动荡影响
周四，股指期货变动不大，交易员仍在努力摆脱关税动荡的影响。此前一天，在英伟达的带动下，纳斯达克综合指数创下新高。 截至发稿，道指期货跌0.04%，标普...
07-10 20:08
ProKidney to Participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference
ProKidney Corp., a leader in cellular therapeutics for chronic kidney disease, announced that senior management will participate in the H.C. Wainwright 4th Annual Kidney Virtual Conference on July 14, 2025, at 1:30 pm ET via a Fireside Chat. The live webcast is available on ProKidney’s website, and investors can contact H.C. Wainwright for one-on-one meetings. ProKidney’s lead product, rilparencel, is a first-in-class cellular therapy in Phase 2 ...
07-09 11:30
